.jpg)
Detect and quantify the BCR-ABL gene fusion with our Quantitative RT-PCR test. Ensure early detection, precise monitoring, and reliable results for effective blood cancer managemen
The BCR-ABL RT-PCR Quantitative test is a precise molecular diagnostic tool that detects and measures the BCR-ABL gene fusion, commonly associated with Chronic Myeloid Leukemia (CML). This test aids in early diagnosis, treatment monitoring, and prognosis evaluation, giving doctors essential insights to manage blood disorders effectively.
How It Works
The test uses Reverse Transcription Polymerase Chain Reaction (RT-PCR) technology to detect and quantify the BCR-ABL fusion gene in blood or bone marrow samples. The process involves:
This precise measurement allows doctors to track minimal residual disease, helping in early intervention and adjustment of therapy.
Importance of the Test
Preparing for the Test
No special preparation is typically required. Your healthcare provider may provide specific instructions if the sample is being taken from bone marrow. Blood samples are usually collected in a routine lab setup with minimal discomfort.
Conclusion
The BCR-ABL RT-PCR Quantitative test is a cornerstone in modern hematology diagnostics, enabling early detection, precise monitoring, and improved management of blood cancers. For a reliable, quick, and accurate testing experience, Diagnopein ensures your health comes first.
No, while the BCR-ABL RT-PCR test is essential for monitoring CML, other tests like bone marrow biopsy and cytogenetic analysis may also be used for initial diagnosis and to evaluate disease characteristics. The RT-PCR test is particularly useful for tracking disease progression and treatment response over time.
The frequency of testing depends on the individual’s treatment plan and response to therapy. Initially, the test is often done every 3-6 months, but the frequency may decrease over time if the patient remains in remission. Regular monitoring helps detect relapse early and ensure continued effectiveness of treatment.
While the test is primarily used for CML and Ph+ ALL, it is also useful in monitoring treatment efficacy and relapse in other types of leukemia or cancers that involve the Philadelphia chromosome.
A blood sample (or bone marrow in some cases) is collected and sent to a laboratory. In the lab, the BCR-ABL mRNA is converted into cDNA using reverse transcription, and then PCR is used to amplify the gene. The amount of BCR-ABL mRNA is quantified, typically in relation to a normal control gene (e.g., ABL1), to determine the level of the fusion gene.
